While immunotherapy with T cell checkpoint inhibitors, targeting PD(L)-1 alone or combined with anti-CTLA-4 antibodies, remains first line treatment for patients with BRAF wild-type advanced (unresectable stage III or stage IV) cutaneous melanoma,17,18 treatment options for patients with BRAF-mutated melanoma include immunotherapy or combined BRAF inhibitor and MEK inhibitor. Here, MAP2K7 is linked to cutaneous melanoma.